|
Volumn , Issue 209, 2001, Pages 799-802
|
Neuroleptic malignant syndrome
a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
3,4 METHYLENEDIOXYAMPHETAMINE;
AMANTADINE;
ANESTHETIC AGENT;
ANTIEMETIC AGENT;
BENZODIAZEPINE DERIVATIVE;
BROMOCRIPTINE;
CHOLINERGIC RECEPTOR BLOCKING AGENT;
COCAINE;
DANTROLENE;
DOPAMINE 2 RECEPTOR BLOCKING AGENT;
DOPAMINE RECEPTOR STIMULATING AGENT;
DROPERIDOL;
LITHIUM SALT;
LORAZEPAM;
METOCLOPRAMIDE;
NEUROLEPTIC AGENT;
PROCHLORPERAZINE;
PROMETHAZINE;
SEDATIVE AGENT;
SUXAMETHONIUM;
CLINICAL FEATURE;
DIFFERENTIAL DIAGNOSIS;
DISEASE COURSE;
ELECTROCONVULSIVE THERAPY;
HUMAN;
MEDICAL LIABILITY;
NEUROLEPTIC MALIGNANT SYNDROME;
PATHOGENESIS;
PATIENT CARE;
PHYSICIAN;
REVIEW;
SAFETY;
SYMPTOMATOLOGY;
TREATMENT OUTCOME;
|
EID: 0034851411
PISSN: 00446394
EISSN: None
Source Type: Journal
DOI: 10.1097/00012995-200108000-00001 Document Type: Review |
Times cited : (29)
|
References (18)
|